The Global Cervical Cancer Treatment Market was valued at USD 5.33 billion in 2020 and is expected to reach USD 7.90 billion in 2027 with a CAGR of 4.8% over the forecast period. Increased disease prevalence, proactive government initiatives, and advent of targeted therapies are the major factors contributing to the market expansion. Cervical cancer has a high mortality rate (nearly 50%), which can be reduced by diagnosis and prevention.
Since the disease progression is generally slow, precancerous changes provide possibilities for prevention and treatment. However, most cases are presented at later stages of disease progression due to lack of awareness or inaccessibility to diagnostic facilities. Human Papillomavirus (HPV) is a major causative factor for cervical cancer, generally acquired through sexual transmission. There are more than 100 strains of HPV, out of which 13 are high-risk or cancerous.
Lack of awareness about the diagnosis and treatment methods, high cost of treatment, and adverse effects associated with cancer therapy may hinder the market growth. Moreover, lack of targeted drugs with improved clinical profile at reduced costs and convenient administration schedule is also likely to obstruct market growth. However, rising R & D expenditure in oncologic diseases offer a promising future for the global cervical cancer treatment market in the foreseeable future.
Report : Cervical Cancer Treatment Market - By Type (Squamous Cell Carcinomas, Adenocarcinomas, Adenosquamous Carcinomas), By Treatment (Surgery, Laser Surgery, Trachelectomy, Radical Hysterectomy, Cryosurgery, Simple Hysterectomy, Other), By End User (Cancer Care Centers, Diagnostic Centers, Pharmacies, Others) and By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, opportunity and Forecast 2020 To 2027